Last reviewed · How we verify
NCT06057805: PPCMS
The PPCGMS Intervention After GDM Trial
NA trial testing Blinded Dexcom G7 CGM in Postpartum Gestational Diabetes Mellitus in 39 participants. Terminated before completion.
16 October 2024
Quick facts
| Lead sponsor | Woman's |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 39 |
| Start date | 6 February 2024 |
| Primary completion | 16 October 2024 |
| Estimated completion | 16 October 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Blinded Dexcom G7 CGM
Conditions studied
- Postpartum Gestational Diabetes Mellitus — all drugs for Postpartum Gestational Diabetes Mellitus →
Sponsor
Woman's — full company profile →
Who can join
Adults 18 to 45, female only, with Postpartum Gestational Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Among women who experience glucose abnormalities during pregnancy, screening during the postpartum period offers a window of opportunity for early identification of diabetes and prediabetes. The rates of postpartum type 2 diabetes (T2D) screening with an OGTT for women with GDM are not optimal given the majority of women with GDM fail to return for postpartum glucose testing. Continuous glucose monitoring (CGM) systems have been recognized as an ideal method of monitoring glycemic control in diabetic patients. CGM has been used in diabetic patients primarily as a management tool allowing a more acceptable and reliable glucose reading and control than self-monitoring of blood glucose (SMBG). There is a need to improve diabetes testing after childbirth in women who experienced gestational diabetes. This will allow investigators to target their efforts to improve the early diagnosis and treatment of diabetes following GDM. No studies conducted to date have not comprehensively examined whether CGM after delivery can be used in women with a recent history to predict their risk of diabetes. This research study is being done to assess the acceptability, feasibility, and accuracy of using a glucose sensor (also known as a continuous glucose monitor or CGM) after childbirth as a diagnostic test that can help identify women who are at risk of developing diabetes after having gestational diabetes and explore its correlation to the standard postpartum oral glucose tolerance test as well as a HbA1c and fructosamine test.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Continuous glucose monitoring predicts glycemic status in postpartum women with a recent history of gestational diabetes.
Elkind-Hirsch KE, Armatta ML, Hames KC, Veillon EW. · · 2026 · PMID 41422557 · DOI 10.1080/17434440.2025.2607631
Verify or expand the search:
- PubMed search for NCT06057805
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Woman's trials
Trials by the same sponsor.
- NCT04873050 — Treatment to Regress to Normoglycemia in Women with a Recent History of GDM · Phase 4 · recruiting
- NCT05067075 — The CGMS in GDM Labor and Delivery Study · NA · completed
- NCT04948112 — Effectiveness of CGMS Vs. Self-monitoring Blood Glucose (SMBG) in Woman with Gestational Diabetes · NA · completed
- NCT04726085 — Ibuprofen Versus Indomethacin Following Emergent Cerclage Placement · NA · terminated
- NCT04256889 — Use Of Nfant(R) Technology Feeding System For Infants Less Than 30 Weeks GA · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06057805 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Woman's
- Last refreshed: 18 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06057805.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing